which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration ... conditions: Alzheimer's disease, progressive supranuclear palsy ...

As Gladstone Institutes commemorates World Alzheimer’s Month, Lennart Mucke, MD, discusses what’s next for Alzheimer’s ...

Ned Pagliarulo Eli Lilly will spend $1 billion to expand a manufacturing site in Limerick, Ireland, from where it plans to produce the active drug ingredient for its newly approved Alzheimer's ...

But what if there were drugs already on the ... Results suggest that estradiol, an FDA-approved estrogen replacement therapy, could be effective for treating Alzheimer's in the APOE genotype.